{"preliminary_commentary":{"by_channel":{"podcast":1,"x_thread":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"EPCORE™ NHL-2","nct_id":"NCT04663347","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=epcore-nhl-2-nct04663347. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EPCORE™ NHL-2","arms":[{"description":"In participants with previously untreated DLBCL.","label":"Arm 1 - Epcoritamab + R-CHOP","type":"EXPERIMENTAL"},{"description":"In participants with R/R FL.","label":"Arm 2 - Epcoritamab + R2","type":"EXPERIMENTAL"},{"description":"In participants with previously untreated FL.","label":"Arm 3 - Epcoritamab + BR","type":"EXPERIMENTAL"},{"description":"In participants with R/R DLBCL eligible for ASCT.","label":"Arm 4 - Epcoritamab + R-DHAX/C","type":"EXPERIMENTAL"},{"description":"In participants with R/R DLBCL ineligible ASCT.","label":"Arm 5 - Epcoritamab + GemOx","type":"EXPERIMENTAL"},{"description":"In participants with previously untreated FL.","label":"Arm 6 - Epcoritamab + R2","type":"EXPERIMENTAL"},{"description":"In participants with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L.","label":"Arm 7 - Epcoritamab maintenance","type":"EXPERIMENTAL"},{"description":"In participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline.","label":"Arm 8 - Epcoritamab + R mini-CHOP","type":"EXPERIMENTAL"},{"description":"In participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy.","label":"Arm 9 - Epcoritamab + Lenalidomide","type":"EXPERIMENTAL"},{"description":"In participants with R/R DLBCL eligible for ASCT.","label":"Arm 10 - Epcoritamab + R-ICE","type":"EXPERIMENTAL"}],"collaborators":["AbbVie"],"completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"conditions":["Diffuse Large B-Cell Lymphoma","Follicular Lymphoma"],"enrollment":{"count":543,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone","otherNames":["R-CHOP"],"type":"DRUG"},{"name":"rituximab and lenalidomide","otherNames":["R2"],"type":"DRUG"},{"name":"rituximab and bendamustine","otherNames":["BR"],"type":"DRUG"},{"name":"rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin","otherNames":["R-DHAX/C"],"type":"DRUG"},{"name":"gemcitabine and oxaliplatin","otherNames":["GemOx"],"type":"DRUG"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone","otherNames":["R mini-CHOP"],"type":"DRUG"},{"name":"Lenalidomide","otherNames":[],"type":"DRUG"},{"name":"rituximab, ifosfamide, carboplatin, and etoposide phosphate","otherNames":["R-ICE"],"type":"DRUG"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Rituximab and Lenalidomide","otherNames":["R2"],"type":"DRUG"},{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3xCD20","EPKINLY™"],"type":"BIOLOGICAL"}],"last_update":"2026-10-06","lead_sponsor":"Genmab","official_title":"A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Number of Participants With Dose limiting Toxicities (DLTs)","timeFrame":"During the first cycle (Cycle length= 28 days) in each cohort"},{"measure":"Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)","timeFrame":"From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)"},{"measure":"Part 2 (Except Arm 7): Overall Response Rate (ORR)","timeFrame":"Up to 3 years"}],"references":[{"citation":"Falchi L, Vermaat JSP, Brody JD, Leslie L, Offner F, Christensen JH, Nijland M, Belada D, Wahlin BE, Drott K, Gomez Prieto P, Kopeckova K, Garcia-Sancho AM, Mei JP, Altintas I, Risum M, Reilly A, Zou J, Abrisqueta P. Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial. Lancet Haematol. 2026 Sep;13(9):e614-e625. doi: 10.1016/S2352-3026(26)00198-5.","pmid":"42660129","type":"DERIVED"},{"citation":"Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie LA, Narkhede MS, Cordoba R, Oki T, Wielgos-Bonvallet M, Khoshdeli M, Hao Y, Archer K, Risum M, Belada D. Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial. Blood. 2026 Aug 11:blood.2026033839. doi: 10.1182/blood.2026033839. Online ahead of print.","pmid":"42622258","type":"DERIVED"},{"citation":"Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellstrom M, Jorgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L. Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial. Haematologica. 2026 Oct 1;111(10):3346-3357. doi: 10.3324/haematol.2025.300086. Epub 2026 Mar 5.","pmid":"41784015","type":"DERIVED"},{"citation":"Falchi L, Sureda A, Leppa S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton KM, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D. Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. 2025 Nov 27;146(22):2629-2640. doi: 10.1182/blood.2025029909.","pmid":"40920572","type":"DERIVED"},{"citation":"Brody JD, Jorgensen J, Belada D, Costello R, Trneny M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, Andre M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830.","pmid":"39792928","type":"DERIVED"}],"start_date":{"date":"2020-11-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","url":"https://clinicaltrials.gov/study/NCT04663347"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/epcore-nhl-2-nct04663347"}